Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06372223 Completed - Clinical trials for Advanced Solid Tumor

A Food Effect Study of SPH5030 Tablets.

Start date: March 4, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the food effect of SPH5030 tablets in healthy Chinese adult subjects.

NCT ID: NCT06266923 Completed - Clinical trials for Advanced Solid Tumor

A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.

Start date: January 20, 2022
Phase: Early Phase 1
Study type: Interventional

To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SPH6516 tablets in the treatment of advanced solid tumors.

NCT ID: NCT06198556 Completed - Clinical trials for Advanced Solid Tumor

Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects

Start date: January 14, 2024
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy adult subjects after oral administration of HRS-1167 tablets. The secondary objective of the study is to evaluate the safety of HRS-1167 alone and when co-administered with rifampicin.

NCT ID: NCT05908773 Completed - Clinical trials for Advanced Solid Tumor

A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors

Start date: April 4, 2023
Phase: Early Phase 1
Study type: Interventional

This is an open-label, single-center, single-arm, phase 0, microdose study in subjects with advanced solid tumors and radiographically confirmed metastases. The study will evaluate delivery of TTX-MC138-NODAGA-Cu64 radiographically and establish the PK and biodistribution of TTX-MC138-NODAGA-Cu64 as determined by PET-MRI. The study consists of 3 parts: a screening period, dosing period, and follow-up period. The estimated total duration of the study is approximately 46 days. Approximately 12 subjects with advanced metastatic solid tumors will be enrolled at 1 single site.

NCT ID: NCT05809336 Completed - Clinical trials for Advanced Solid Tumor

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Start date: May 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

We conducted a single-center, prospective randomized ,Parallel controls, open labels Clinical Studies,The study is about Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients with malignant Advanced Solid Tumors .One group was the inosine group , the other group was the non-inosine group.The treatment regimen of inosine group : inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting, and the treatment regimen of non-inosine group : PD-1/PD-L1 inhibitor ± chemotherapy/targeting.The primary study endpoints were overall survival (OS) and progression-free survival PFS, and the secondary study endpoints were objective remission rate (ORR) and disease control rate (DCR) comparing the two groups.

NCT ID: NCT05508100 Completed - Clinical trials for Advanced Solid Tumor

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Start date: September 9, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of IO-108 monotherapy and in combination with anti-PD-1 monoclonal antibody pembrolizumab or tislelizumab in adult patients with advanced solid tumors. The study will be conducted in 3 parts, including Part A IO-108 monotherapy dose confirmation; Part B IO-108 + anti-PD-1 dose confirmation, and Part C dose expansion.

NCT ID: NCT05382936 Completed - Clinical trials for Advanced Solid Tumor

Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid Tumors

Start date: March 19, 2021
Phase: Phase 1
Study type: Interventional

Study STML-901-0119 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-901 in patients with Advanced Solid Tumors.

NCT ID: NCT05246111 Completed - Clinical trials for Advanced Solid Tumor

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

Start date: February 15, 2022
Phase: Phase 1
Study type: Interventional

The study will be conducted in two periods, Period 1 (mass balance) and Period 2 (extension). The purpose of Period 1 of this study is to provide a quantitative characterization of the mass balance, rates and routes of elimination, and metabolic pathways after a single intravenous administration of [14C]berzosertib. The purpose of Period 2 is to assess safety and efficacy of berzosertib in combination with topotecan.

NCT ID: NCT05231746 Completed - Clinical trials for Advanced Solid Tumor

A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)

Start date: April 18, 2022
Phase: Phase 1
Study type: Interventional

The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.

NCT ID: NCT05126433 Completed - Clinical trials for Advanced Solid Tumor

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201)

EMERGE-201
Start date: March 3, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.